AliveCor has received approval from the US Food and Drug Administration (FDA) for its KardiaMobile six-lead private electrocardiogram (ECG) machine.
Claimed to be the world’s first six-lead private ECG system, the KardiaMobile 6L will show physicians an in-depth view of sufferers’ hearts as well as the visibility into certain arrhythmias which are primary indicators of heart problems.
AliveCor CEO Ira Bahr stated: “KardiaMobile 6L is the most clinically beneficial private ECG ever created, and another crucial step in AliveCor’s march to creating coronary heart care convenient, easily accessible, and cheaper than ever.”
KardiaMobile six-lead system is claimed to be consistent in design with AliveCor’s present KardiaMobile. An auxiliary electrode on the underside is provided, along with the two wires on the top of the machine.
A person has to position thumbs on the two high electrodes, whereas the bottom wire on their left knee or ankle.
In cardiology, this formation is named as Einthoven Triangle, which permits cardiologists to view electrical exercise within the coronary heart from six views or leads.
A six-lead ECG provides physicians with a magnificent view of the center in comparison with a single lead ECG, serving to detect a variety of arrhythmias and different coronary heart conditions.
Scripps Analysis Translational Institute director and founder, Dr. Eric Topol, stated: “I’m impressed with the standard and ease of 6-lead mobile ECG tracings which can unquestionably sharpen our potential to diagnose coronary heart rhythm and conduction abnormalities. It’s a welcome and a much-needed step ahead for mobile coronary heart diagnostics.”
The corporate plans to make KardiaMobile 6L machine accessible to the customers in June.